Ultra-hypofractionated radiotherapy for the treatment of localized prostate cancer : Results, limits and prospects
Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved..
Still an emerging approach a few years ago, stereotactic body radiation therapy (SBRT) has ranked as a valid option for the treatment of localized prostate cancer. Inherent properties of prostatic adenocarcinoma (low α/β) make it the perfect candidate. We propose a critical review of the literature trying to put results into perspective to identify their strengths, limits and axes of development. Technically sophisticated, the stereotactic irradiation of the prostate is well tolerated. Despite the fact that median follow-up of published data is still limited, ultra-hypofractionated radiotherapy seems very efficient for the treatment of low and intermediate risk prostate cancers. Data seem satisfying for high-risk cancers as well. New developments are being studied with a main interest in treatment intensification for unfavorable intermediate risk and high-risk cancers. Advantage is taken of the sharp dose gradient of stereotactic radiotherapy to offer safe reirradiation to patients with local recurrence in a previously irradiated area.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 25(2021), 6-7 vom: 01. Okt., Seite 684-691 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Radiothérapie en hypofractionnement extrême appliquée au traitement du cancer localisé de la prostate : résultats, limites et perspectives |
|---|
| Beteiligte Personen: |
Graff, P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.09.2021 Date Revised 30.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2021.06.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328195944 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328195944 | ||
| 003 | DE-627 | ||
| 005 | 20231225202434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.canrad.2021.06.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328195944 | ||
| 035 | |a (NLM)34274223 | ||
| 035 | |a (PII)S1278-3218(21)00127-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Graff, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ultra-hypofractionated radiotherapy for the treatment of localized prostate cancer |b Results, limits and prospects |
| 246 | 3 | 3 | |a Radiothérapie en hypofractionnement extrême appliquée au traitement du cancer localisé de la prostate : résultats, limites et perspectives |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.09.2021 | ||
| 500 | |a Date Revised 30.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Still an emerging approach a few years ago, stereotactic body radiation therapy (SBRT) has ranked as a valid option for the treatment of localized prostate cancer. Inherent properties of prostatic adenocarcinoma (low α/β) make it the perfect candidate. We propose a critical review of the literature trying to put results into perspective to identify their strengths, limits and axes of development. Technically sophisticated, the stereotactic irradiation of the prostate is well tolerated. Despite the fact that median follow-up of published data is still limited, ultra-hypofractionated radiotherapy seems very efficient for the treatment of low and intermediate risk prostate cancers. Data seem satisfying for high-risk cancers as well. New developments are being studied with a main interest in treatment intensification for unfavorable intermediate risk and high-risk cancers. Advantage is taken of the sharp dose gradient of stereotactic radiotherapy to offer safe reirradiation to patients with local recurrence in a previously irradiated area | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer de la prostate | |
| 650 | 4 | |a Cancer localisé | |
| 650 | 4 | |a Hypofractionnement extrême | |
| 650 | 4 | |a Localized cancer | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Radiothérapie | |
| 650 | 4 | |a Stereotactic irradiation | |
| 650 | 4 | |a Stéréotaxie | |
| 650 | 4 | |a Ultra-hypofractionation | |
| 700 | 1 | |a Crehange, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 25(2021), 6-7 vom: 01. Okt., Seite 684-691 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:6-7 |g day:01 |g month:10 |g pages:684-691 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2021.06.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 6-7 |b 01 |c 10 |h 684-691 | ||